Skip to content

Adalimumab in Adult Japanese Subjects With Psoriasis

Adalimumab in Adult Japanese Subjects With Psoriasis 1

Clinical Trial: Adalimumab in Adult Japanese Subjects With Psoriasis. Safety of Adalimumab in Japanese Subjects With Generalized Pustular Psoriasis (GPP) ClinicalTrials. Efficacy and Safety of Adalimumab in Subjects With Moderately to Severely Acute Ulcerative Colitis Completed Ulcerative Colitis April 7, 2011 NCT00385736 A Study in Rheumatoid Arthritis (RA) Patients to Compare Two Formulations of Adalimumab for Pharmacokinetic, Pharmacodynamic and Safety Completed Rheumatoid Arthritis June 10, 2014 NCT01712178 Efficacy and Safety of Adalimumab in Patients With Active Rheumatoid Arthritis Treated Concomitantly With Methotrexate. Subjects will receive infliximab infusions (5 mg/kg.

Adalimumab in Adult Japanese Subjects With Psoriasis 2Abbott; Abbott Japan Co.,Ltd; Eisai Limited. Phases: Phase II; Phase III. Indications, Acronym: Psoriasis. Age Groups: Adult; Senior. Gender: Both. Names:. Adalimumab is a biological therapy often used for treating psoriasis. More recently, two large-scale trials have assessed the safety and efficacy of adalimumab in adult patients with chronic plaque psoriasis. Only studies in which adult subjects received a biologic agent for at least one year were included, and those studies in which subjects were treated with a combination of a biologic therapy and another systemic agent were excluded from this review. The efficacy and safety of adalimumab were evaluated in a Phase 3 randomized, controlled evaluation every other week dosing in moderate-to-severe psoriasis (REVEAL). Efficacy and safety of ustekinumab in Japanese patients with moderate-to-severe plaque-type psoriasis: long-term results from a phase 2/3 clinical trial.

Meanwhile, adalimumab had the best cost-efficacy, followed by ustekinumab 45 mg and infliximab. The inclusion criteria of studies were randomized placebo-controlled trials which assessed the efficacy of etanercept, adalimumab, infliximab, and ustekinumab in treating moderate to severe psoriasis in adults by using the FDA-approved regimens for at least 6 months. The purpose of this research study is to compare the efficacy and safety of ABP 501 and Adalimumab (Humira) in adult subjects with plaque psoriasis.

Nct00647400 Clinical Trial Information

Efficacy And Cost-efficacy Of Biologic Therapies For Moderate To Severe Psoriasis: A Meta-analysis And Cost-efficacy Analysis Using The Intention-to-treat Principle